What Can U Use For Round Table Cloths 84 In

The Truth About Drugs Antidiabetic

Suspension of permission marketing antidiabetic drugs containing rosiglitazone (Avandia ®, Avandamet ®, Avaglim ®).

The European Medicines Agency (EMA) recommends suspension of authorizations to market-based drugs rosiglitazone (Avandia ®, Avandamet ®, Avaglim ®). This suspension follows the re-evaluation by the European Medicines Evaluation Human Use (CHMP) which concluded that the risk / benefit ratio was unfavorable due to the increased cardiovascular risk. The reassessment of recent data, announced last July, confirmed the increased cardiovascular risk, mainly the occurrence of myocardial infarction and stroke in relation to the expected benefits of reducing blood sugar.

Afssaps asks patients currently treated with a drug containing rosiglitazone not stop their treatment without seeking the advice of their doctor, and consult in the coming weeks to adjust their diabetes treatment. Right now, doctors should prescribe more drugs containing rosiglitazone.
Rosiglitazone belongs to a class of oral antidiabetic drugs, the glitazones used to treat type 2 diabetes for improved glycemic control and prevention of complications related to diabetic microangiopathy, affecting in particular the retina and kidney. Three specialties have an authorization for the European market: Avandia ® (rosiglitazone) in 2000, Avandamet ® (Rosiglitazone and metformin) in 2003 and Avaglim ® (rosiglitazone and glimepiride) in 2006. Only the first two drugs are marketed in France. Since the communication of Afssaps in January 2008, informing them of the restrictions on use of rosiglitazone in patients with ischemic heart disease, consumption of drugs containing rosiglitazone decreased by 50%. To date, approximately 110,000 patients are treated with rosiglitazone.
examination of all available data (meta-analysis, epidemiological studies and clinical trials) with rosiglitazone led the European Medicines Agency (EMA) to request the suspension of authorizations for the marketing of drugs containing this active ingredient. The revaluation undertaken at the request of the European Commission, concerned especially the cardiovascular risk of these drugs.
In 2008, an initial assessment had already led the European health authorities to restrict the use of rosiglitazone in patients with ischemic cardiovascular diseases, and this both for beginners as for continued treatment. Afssaps states that rosiglitazone is indicated in France in second-line after failure or intolerance other oral antidiabetic drugs.



Afssaps asks patients currently treated with a drug containing rosiglitazone not stop their treatment without seeking the advice of their doctor and consult in the coming weeks to adapt their antidiabetic . Now, doctors should prescribe more drugs containing rosiglitazone.

Source: http://www.afssaps.fr/


-> When will we tell the truth for diabetics? The fact that their illness is caused by a diet too rich in carbohydrate and too low in micronutrients!


... We must pass the Knowledge and Truth ... ...
Truth always ends up Know ...

DJAMELITO